CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade 180 Life Sciences Corp. - ATNF CFD

0.38
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.41
Open* 0.39
1-Year Change* -15.22%
Day's Range* 0.39 - 0.41
52 wk Range 0.35-6.96
Average Volume (10 days) 143.34K
Average Volume (3 months) 4.22M
Market Cap 17.78M
P/E Ratio -100.00K
Shares Outstanding 40.46M
Revenue N/A
EPS -0.39
Dividend (Yield %) N/A
Beta 0.41
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 17, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
Nov 14, 2023 0.40 0.00 0.00% 0.40 0.40 0.40
Nov 13, 2023 0.41 0.02 5.13% 0.39 0.41 0.39
Nov 8, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
Nov 6, 2023 0.40 0.00 0.00% 0.40 0.40 0.39
Nov 3, 2023 0.42 0.00 0.00% 0.42 0.42 0.42
Nov 2, 2023 0.41 0.00 0.00% 0.41 0.41 0.41
Nov 1, 2023 0.40 0.01 2.56% 0.39 0.40 0.39
Oct 31, 2023 0.40 0.01 2.56% 0.39 0.41 0.39
Oct 30, 2023 0.40 -0.01 -2.44% 0.41 0.41 0.39
Oct 27, 2023 0.41 -0.01 -2.38% 0.42 0.42 0.41
Oct 26, 2023 0.41 0.00 0.00% 0.41 0.41 0.41
Oct 25, 2023 0.42 0.03 7.69% 0.39 0.42 0.39
Oct 24, 2023 0.43 -0.01 -2.27% 0.44 0.44 0.43
Oct 20, 2023 0.41 0.02 5.13% 0.39 0.41 0.38
Oct 19, 2023 0.42 -0.08 -16.00% 0.50 0.51 0.42
Oct 18, 2023 0.47 -0.02 -4.08% 0.49 0.50 0.46
Oct 17, 2023 0.48 -0.02 -4.00% 0.50 0.51 0.48
Oct 16, 2023 0.49 -0.04 -7.55% 0.53 0.53 0.49
Oct 13, 2023 0.53 0.00 0.00% 0.53 0.53 0.53

180 Life Sciences Corp. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 0 0 0 0 0
Total Operating Expense 15.6507 8.22877 1.20894 0.59908 0.34388
Selling/General/Admin. Expenses, Total 11.5764 3.23827 1.20894 0.59908 0.34388
Operating Income -15.6507 -8.22877 -1.20894 -0.59908 -0.34388
Net Income Before Taxes -20.3479 -10.9045 0.16596 1.45373 0.31913
Net Income After Taxes -20.3246 -10.8841 -0.0913 1.04054 0.12376
Net Income Before Extra. Items -20.3246 -10.8841 -0.0913 1.04054 0.12376
Net Income -20.3246 -10.8841 -0.0913 1.04054 0.12376
Income Available to Common Excl. Extra. Items -20.3246 -12.0068 -0.0913 1.04054 0.12376
Income Available to Common Incl. Extra. Items -20.3246 -12.0068 -0.0913 1.04054 0.12376
Dilution Adjustment
Diluted Net Income -20.3246 -12.0068 -0.0913 1.04054 0.12376
Diluted Weighted Average Shares 31.3554 18.1541 4.22379 14.8775 9.43508
Diluted EPS Excluding Extraordinary Items -0.6482 -0.66138 -0.02162 0.06994 0.01312
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.66721 -0.56765 -0.02162 0.06994 0.01312
Interest Income (Expense), Net Non-Operating -4.8636 -2.90328 1.3749 2.05281 0.66302
Research & Development 3.94831 2.293
Depreciation / Amortization 0.1163 0.11684
Unusual Expense (Income) 0.00974 2.58066
Other Operating Expenses, Total 0
Gain (Loss) on Sale of Assets 0.92683 -0.03717
Other, Net -0.76035 0.26474
Total Adjustments to Net Income 0 -1.1227
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 3.68107 4.46206 4.21748 4.01317 2.95804
Selling/General/Admin. Expenses, Total 2.97441 2.49055 3.60212 3.01867 2.58135
Research & Development 0.70666 1.97151 0.61535 0.9945 0.36695
Unusual Expense (Income) 0 0 0 0.00974
Operating Income -3.68107 -4.46206 -4.21748 -4.01317 -2.95804
Interest Income (Expense), Net Non-Operating 5.22726 5.65165 22.0237 -19.1828 -13.3562
Gain (Loss) on Sale of Assets 0 -0.00087 0.47268 -0.26874 0.72376
Other, Net 0.01752 -0.15913 0.01231 0 -0.61352
Net Income Before Taxes 1.56371 1.0296 18.2912 -23.4647 -16.204
Net Income After Taxes 1.56371 1.03622 18.2969 -23.4591 -16.1986
Net Income Before Extra. Items 1.56371 1.03622 18.2969 -23.4591 -16.1986
Net Income 1.56371 1.03622 18.2969 -23.4591 -16.1986
Income Available to Common Excl. Extra. Items 1.56371 1.03622 18.2969 -23.4591 -16.1986
Income Available to Common Incl. Extra. Items 1.56371 1.03622 18.2969 -23.4591 -16.1986
Diluted Net Income 1.70344 1.03622 18.2969 -23.4591 -16.1986
Diluted Weighted Average Shares 34.0688 33.9485 33.7096 31.4592 27.9533
Diluted EPS Excluding Extraordinary Items 0.05 0.03052 0.54278 -0.7457 -0.57949
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.05 0.03054 0.53366 -0.74015 -0.59609
Dilution Adjustment 0.13973
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 11.2011 4.01496 0.62406 0.27088 0.47034
Cash and Short Term Investments 8.22451 2.10854 0.54664 0.27088 0.42839
Cash 8.22451 2.10854 0.54664 0.27088 0.42839
Total Assets 62.7137 55.5334 12.5017 118.437 117.058
Other Long Term Assets, Total 0
Total Current Liabilities 19.6993 21.4644 3.1296 0.54607 0.20813
Payable/Accrued 0.26842 0.09472 0.02454
Notes Payable/Short Term Debt 0.08128 2.69928 2.06617 0 0
Total Liabilities 23.391 25.2465 7.1546 4.57107 4.23313
Total Long Term Debt 0.04817 0.11376 0 0 0
Total Equity 39.3227 30.2869 5.34712 113.866 112.825
Common Stock 0.0034 0.00262 0.34755 108.866 107.826
Additional Paid-In Capital 107.184 78.005 3.92966 3.8384 4.87893
Retained Earnings (Accumulated Deficit) -68.6823 -48.3576 1.0699 1.1612 0.12066
Total Liabilities & Shareholders’ Equity 62.7137 55.5334 12.5017 118.437 117.058
Total Common Shares Outstanding 34.0359 26.1712 4.45815 4.09871 14.8775
Prepaid Expenses 2.20124 1.00327 0.05179 0 0.04194
Long Term Investments 11.8777 118.166 116.588
Other Current Liabilities, Total 15.2204 4.44297 0.795 0.45135 0.18359
Other Liabilities, Total 4.025 4.025 4.025
Total Receivables, Net 0.69456 0.79906 0.02563
Other Current Assets, Total 0.08078 0.10408
Property/Plant/Equipment, Total - Net 0
Goodwill, Net 36.9879 36.9008
Intangibles, Net 14.5247 14.6176
Accounts Payable 0.58661 8.74475
Accrued Expenses 1.98295 4.60896
Current Port. of LT Debt/Capital Leases 1.82808 0.96845
Long Term Debt 0.04817 0.11376
Deferred Income Tax 3.64353 3.66833
Other Equity, Total 0.81744 0.63689
Total Preferred Shares Outstanding 0 0
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 8.95651 11.2011 13.6337 4.04576 8.29803
Cash and Short Term Investments 5.66892 8.22451 11.6878 1.83564 6.05286
Cash 5.66892 8.22451 11.6878 1.83564 6.05286
Total Receivables, Net 0 0 0 0.3
Prepaid Expenses 3.2876 2.97658 1.94594 2.21012 1.94517
Total Assets 59.6773 62.7137 65.0698 56.2655 60.1122
Goodwill, Net 36.3235 36.9879 36.8964 37.5613 37.1829
Intangibles, Net 14.3973 14.5247 14.5396 14.6584 14.6312
Total Current Liabilities 15.108 19.6993 24.2248 49.799 33.6222
Accounts Payable 1.03907 0.58661 0.64303 2.53949 4.1418
Accrued Expenses 2.69618 1.98295 2.33594 2.21016 3.39794
Notes Payable/Short Term Debt 0.08603 0.08128 0.08124 1.09097 1.10025
Current Port. of LT Debt/Capital Leases 1.29647 1.82808 0.27929 0.42605 0.6063
Other Current Liabilities, Total 9.99025 15.2204 20.8853 43.5323 24.3759
Total Liabilities 18.7728 23.391 27.929 53.5493 37.4029
Total Long Term Debt 0.04361 0.04817 0.0521 0.07002 0.10796
Long Term Debt 0.04361 0.04817 0.0521 0.07002 0.10796
Deferred Income Tax 3.62119 3.64353 3.65205 3.68027 3.67271
Total Equity 40.9045 39.3227 37.1408 2.71617 22.7093
Common Stock 0.00341 0.0034 0.0034 0.00311 0.00305
Additional Paid-In Capital 107.93 107.184 106.154 89.4957 86.4362
Retained Earnings (Accumulated Deficit) -67.1186 -68.6823 -69.7185 -88.0154 -64.5562
Other Equity, Total 0.08936 0.81744 0.7019 1.23272 0.82623
Total Liabilities & Shareholders’ Equity 59.6773 62.7137 65.0698 56.2655 60.1122
Total Common Shares Outstanding 34.0872 34.0359 33.9687 31.0613 30.5183
Total Preferred Shares Outstanding 0 0 0
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -20.3246 -10.8841 -0.0913 1.04054 0.12376
Cash From Operating Activities -19.3714 -3.87196 -1.45224 -0.78923 -0.49736
Changes in Working Capital -8.20282 2.7287 0.01396 0.22304 0.0419
Cash From Financing Activities 25.4119 -8.73393 -106.509 0.15684 116.784
Financing Cash Flow Items -2.05513 -0.13769 0.74048 0.15684 4.7985
Issuance (Retirement) of Stock, Net 26.6662 -8.93399 -108.427 0 112.125
Issuance (Retirement) of Debt, Net 0.80085 0.33776 1.17823 0 -0.14
Net Change in Cash 6.11596 2.02515 0.27575 -0.15751 0.36114
Non-Cash Items 9.0709 4.17849 -1.3749 -2.05281 -0.66302
Cash Taxes Paid 0 0 0.29734 0.36911 0.225
Cash From Investing Activities 0 14.4907 108.237 0.47488 -115.925
Other Investing Cash Flow Items, Total 0 14.4907 108.237 0.47488 -115.925
Cash From Operating Activities 0.12533
Deferred Taxes -0.0248 -0.02043
Cash Interest Paid 0.03535 0
Capital Expenditures 0
Foreign Exchange Effects 0.07547 0.14031
Amortization 0.10995
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line 1.56371 -20.3246 -21.3609 -39.6577 -16.1986
Cash From Operating Activities -2.07293 -19.3714 -14.3439 -10.3412 -6.33005
Amortization 0.02646 0.10995 0.09314 0.05819 0.02867
Deferred Taxes -0.02233 -0.0248 -0.01659 -0.01098 -0.0054
Non-Cash Items -4.50145 9.0709 13.7434 35.3539 14.5425
Cash Interest Paid 0.00285 0.03535 0.03143 0
Changes in Working Capital 0.86068 -8.20282 -6.803 -6.08465 -4.69721
Cash From Financing Activities -0.51542 25.4119 23.8629 10.134 10.3625
Issuance (Retirement) of Stock, Net 0 26.6662 26.6662 11.6662 10.7311
Issuance (Retirement) of Debt, Net -0.51542 0.80085 -0.7482 -0.59707 -0.36853
Foreign Exchange Effects 0.03276 0.07547 0.06028 -0.06568 -0.08818
Net Change in Cash -2.55559 6.11596 9.57926 -0.27291 3.94432
Financing Cash Flow Items -2.05513 -2.05513 -0.93513
Cash Taxes Paid 0 0
Cash From Investing Activities 0
Other Investing Cash Flow Items, Total 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

180 Life Sciences Corp. Company profile

About 180 Life Sciences Corp

180 Life Sciences Corp. is a clinical stage biotechnology company. The Company is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and inflammatory diseases. The Company has three product development platforms each of which focused on different diseases, pains or medical conditions and target different factors, molecules or proteins, and has their own product candidates, including Anti-TNF, which focusing on fibrosis and anti-tumour necrosis factor (anti-TNF); SCAs focused on drugs, which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs); and α7nAChR focusing on alpha 7 nicotinic acetylcholine receptor (α7nAChR). It conducting clinical trials only for certain indications under the anti-TNF platform. Out of its three product development platforms, only the SCAs platform, involves products that are related to CBD.

Financial summary

BRIEF: For the nine months ended 30 September 2021, 180 Life Sciences Corp revenues was not reported. Net loss increased from $9M to $21.4M. Higher net loss reflects General and administrative increase of 58% to $8.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.90 to -$0.77.

Industry: Bio Therapeutic Drugs

3000 El Camino Real
Bldg 4, Ste 200
94306

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.58 Price
+3.910% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

17,910.50 Price
-0.020% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

78.42 Price
+1.280% 1D Chg, %
Long position overnight fee 0.0111%
Short position overnight fee -0.0330%
Overnight fee time 22:00 (UTC)
Spread 0.030

BTC/USD

56,916.30 Price
+3.910% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading